Dainippon Sumitomo Pharma America Selects SAS® Solutions OnDemand
News Nov 03, 2009
SAS has announced that Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. pharmaceutical company, has selected SAS Solutions OnDemand: Drug Development as a technology platform for clinical development. With SAS OnDemand, DSPA will have a globally accessible, fully regulatory compliant repository for all of its clinical data.
The SAS OnDemand service has allowed DSPA to move with limited internal resources, in creating its centralized SAS development environment. By letting SAS handle all system provisioning and deployment activities, DSPA resources are free to focus on other mission critical business activities.
SAS Solutions OnDemand: Drug Development is a cost-effective alternative to an enterprise SAS Drug Development implementation, with all embedded enterprise-level content management and analytical capabilities. SAS, through its OnDemand solution, directly supports all hardware and software installation, system administration, validation and maintenance, freeing DSPA from these burdensome responsibilities.
As electronics become smaller and faster, the adoption of "wearables", like smart watches, has increased. However, like regular computers, wearables are vulnerable to conventional hacking. What if we could use the human body itself to transfer and collect information? This area of research is known as human body communication (HBC).